Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says

FDA is in the process of developing a policy for including results from studies conducted under the Best Pharmaceuticals for Children Act in labeling, Office of Medical Policy Director Temple says during House hearing on antidepressants.